@reggierabbit why would they do that when they have already demonstrated efficacy in multiple trials, it is being used in other nations, they have a leading world renowned professor in paediatric oncology (Joanne kurtzberg) who has witnessed the results first hand and supports its use, has no safety concerns, msb can really only do a single arm trial in paediatric patients and silviu has already demonstrated why the results are positive compared to previous trials due to the less potent stem cells with poor quality control? That’s just ridiculous
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-683
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161000 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 50400 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |